Login to Your Account

Clinic Roundup

Tuesday, April 19, 2011
Cytokinetics Inc., of South San Francisco, said additional Phase IIa data of CK-2017357 in patients with amyotrophic lateral sclerosis showed that, at 24 hours after each of the 250-mg and 500-mg doses, dose-related increases in the change from the day one baseline in percent predicted muscle strength achieved nominal statistical significance for elbow flexion (p = 0.005 and 0.0004, respectively).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription